Pacira BioSciences, Inc. (NASDAQ: PCRX) Q2 2025 Earnings | 08/06/2025

11 days ago

44:12

Inside Ticker

Earnings Calls

About this video

Pacira BioSciences, Inc. reported its second quarter 2025 financial results with total revenues of $181.1 million, representing a 1.7% increase from the prior year but slightly missing analyst expectations of $183 million. The company posted a net loss of $4.8 million, or $(0.11) per share, which was wider than some estimates. However, adjusted earnings per share (EPS) beat expectations at $0.74, reflecting strong operational performance. Adjusted net income was $36 million, above consensus estimates, and adjusted EBITDA came in at $54.3 million, also beating forecasts. Sales growth was led by EXPAREL, which saw a 4% increase in sales to $142.9 million driven by 6% volume growth. ZILRETTA sales contributed $31.3 million, supported by strategic collaboration to expand market reach. The iovera° product line generated $5.6 million in sales, comparable to the prior year period. Gross margins improved due to manufacturing efficiencies and scale. Pacira announced a narrowing of its full-year 2025 revenue guidance to a range between $730 million and $750 million. The company also raised its non-GAAP gross margin forecast to 78-80%, maintained its R&D expense guidance at $90 million to $105 million, and projected non-GAAP selling, general, and administrative (SG&A) expenses to be between $290 million and $320 million. At quarter-end, Pacira held $445.9 million in cash and investments, providing a strong liquidity position to support ongoing commercial and operational initiatives. The company demonstrated confidence in its strategy with a recent share repurchase of 2 million shares costing $50 million. About Inside Ticker: For more expert analysis and real-time updates on Pacira BioSciences, Inc. (NASDAQ: PCRX) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #PaciraBioSciences #PCRX #Q22025 #Earnings #FinancialResults #Revenue #NetLoss #AdjustedEPS #EXPAREL #ZILRETTA #Iovera #GrossMargin #Guidance #R&D #SG&A #ShareRepurchase #Pharma #Biotech #MedicalProducts #Innovation #InsideTicker #2025Outlook

Important Note: The stock market is inherently unpredictable, and forecasts are subject to change based on various factors, including economic conditions and company performance. Always consult multiple sources and consider professional advice before making investment decisions.

AI-Powered Financial Analysis This analysis uses real-time market data. While we strive for accuracy, always verify important financial information and consult with qualified financial professionals before making investment decisions. Past performance does not guarantee future results.